stable angina

systematic review meta-analysis network meta-analysis

Select myocardial revascularizationspinal cord stimulationantithromboticsanti-anginal drugsantibioticsHR-slowing agents All type of patientDiabetic patientsmultivessels diseasepatients with left ventricular dysfunctionuncoded clinical condition ***single vessel disease       antibioticsaspirinbioabsorbable polymer stentCABG or PCIclopidogreldipyridamoldrug-eluting stentsfractional-flow-reserve-guidedivabradineivabradine + beta-blockersivabradine + calcium blockernon-polymeric ESoral platelet GP IIbIIIa receptor inhibitorPCIranolazinespinal cord stimulationsurgeryticlopidinetransmyocardial revascularization angioplastyaspirinAzithromycinbiolimus eluting stentclarithromycinclopidogrelCoronary Artery Bypass Surgerydactinomycin eluting stentdipyridamoldrug-eluting stentseverolimus eluting stentivabradinepaclitaxelPCIPTCAranolazinesirolimus eluting stentticlopidinezotarolimus eluting stent vs angioplastyvs bare-metalvs medical treatmentvs no PCIvs placebovs placebo or controlvs aspirinvs beta-blockersvs calcium blockersvs drug-eluting stentsvs no TMRvs non active controlvs Surgery      

Filter

Group by Group by... nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition MA  in first nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in second nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in third	Description Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation					Results Global trial result Main results All results All result tag NCT results	All cause death (124)myocardial infarction (fatal and non fatal) (72)CABG (58)PTCA (51)target lesion revascularisation (47)MACE (47)Stent thrombosis (any, end of follow up) (46)Cardiac death or MI (38)cardiac death (36)Non fatal MI (35)Long term death (32)Deaths or MI (30)angiographic restenosis (28)4y stent thrombosis (ARC) (22)late stent thrombosis (31days - 1year) (21)target-vessel revascularization (19)Angina (16)long term cardiovascular events (15)1 year event (12)cardiovascular events (12)1 year death from any cause (11)Acute coronary syndrome (11)sub acute stent thrombosis (1-30 days) (11)long term MI (10)1 year revascularization (10)Acute stent thrombosis (<=24h) (9)Cardiovascular death (9)2 yr MACE (9)5-year death (9)Angina (grade 2 or worse) in first year (8)6 months MI (8)6 months death (8)In-hospital death (7)stroke (fatal and non fatal) (7)urgent CABG (6)In-hospital MI (6)6 months events (6) (6)7-year death (6)10-year death (6)Non fatal stroke (6)Non vascular death (6)2 yr TLR (5)1 year MI (5)Revascularization (4)Angina relief (4)Bleeding (3)in-lesion binary restenosis (3)4 yr stent thrombosis (3)death or hospitalization for cardiac causes (3)4 yr mortality from all causes (2)4 yr MI (2)4 yr death or MI (2)Repeat revascularization (2)Coronary event (2)4 yr TLR (2)Death, MI and stroke (1)2 yr Death (all cause) (1)cardiac event (fatal and non fatal ) (1)hospitalisation for cardiovascular causes (1)Definite or probable stent thrombosis (1)Urgent revascularization (1) Options Numeric bar chart forest plot medians
Trial	Studied trt	Control trt	patients	tags	ROB	Trial result	All cause death	myocardial infarction (fatal and non fatal)
anti-anginal drugs
ranolazine
MARIZA, 2004	ranolazine 1000mg	placebo			Low risk of bias	-
RAN080, 2005	ranolazine 1000mg	placebo			Low risk of bias	-
CARISA 1000mg, 2004	ranolazine 1000mg	placebo (on top standard treatment)			Low risk of bias	negative
ERICA, 2006      NCT	ranolazine 1000mg + amlodipine	placebo + amlodipine			Low risk of bias	-
antibiotics
not classified
PROVE-IT, 2005	Gatifloxacin	placebo			Low risk of bias	negative
ROXIS, 1999	Roxithromycin	placebo			Low risk of bias	negative
Leowattana et al, 2001	Roxithromycin	placebo				negative
ANTIBIO, 2003	Roxithromycin	placebo			Low risk of bias	negative
Azithromycin
Gupta et al, 1997	Azithromycin	placebo			Low risk of bias	negative
ACADEMIC, 1999	Azithromycin	placebo			Low risk of bias	negative
WIZARD, 2003	Azithromycin	placebo			Low risk of bias	negative
ACES, 2005      NCT	Azithromycin	placebo			Low risk of bias	negative
STAMINA (Azithromycin), 2002	Azithromycin	placebo			Low risk of bias	negative
AZACS, 2003	Azithromycin	placebo			Low risk of bias	negative
clarithromycin
CLARIFY, 2001	clarithromycin	placebo			Low risk of bias	suggesting
CLARICOR, 2006    NCT	clarithromycin	placebo			Low risk of bias	negative
antithrombotics
not classified
Murphy, 2003	roxifiban	placebo			Low risk of bias	-
aspirin
SAPAT, 1992	aspirin	placebo			Low risk of bias	suggesting
clopidogrel
ASCET    NCT	clopidogrel	aspirin			Risk of bias	negative
dipyridamol
Atlanta (Sbar), 1967	dipyridamol	control			Low risk of bias	negative
Becker, 1967	dipyridamol	control			Low risk of bias	negative
Wirecki, 1967	dipyridamol	control			Low risk of bias	negative
Igloe, 1970	dipyridamol	placebo			Low risk of bias	-
Zion, 1961	dipyridamol	placebo			Low risk of bias	-
Kinsella, 1962	dipyridamol	placebo			Low risk of bias	-
Leiberman, 1964	dipyridamol	placebo			Low risk of bias	-
Dewar, 1961	dipyridamol	placebo			Low risk of bias	-
Neumann, 1964	dipyridamol	placebo			Low risk of bias	-
Foulds, 1960	dipyridamol	placebo			Low risk of bias	-
ticlopidine
Berglund, 1985	ticlopidine	placebo			Low risk of bias	negative
HR-slowing agents
ivabradine
Borer (CL2-009) 10mg, 2003	ivabradine 10mg	placebo			Low risk of bias	-
BEAUTIFUL, 2008    NCT	ivabradine 15mg	placebo			Low risk of bias	negative
Borer (CL2-009) 20mg, 2003	ivabradine 20mg	placebo			Low risk of bias	-
SIGNIFY, 2014	ivabradine 20mg	placebo			Low risk of bias	negative
Borer (CL2-009) 5mg, 2003	ivabradine 5mg	placebo			Low risk of bias	-
BEAUTIFUL (angina subgroup)	ivabradine 15mg	placebo (on top standard treatment)			Low risk of bias	suggesting
CL3-018 10mg	ivabradine 10mg	placebo on top of amlodipine				-
CL3-018 15mg	ivabradine 15mg	placebo on top of amlodipine				-
ASSOCIATE (Tardif), 2009    NCT	ivabradine 15mg	placebo on top of atenolol			Low risk of bias	-
CL3-023 (15mg)	ivabradine	amlodipine			Low risk of bias	-
CL3-023 (20mg)	ivabradine	amlodipine			Low risk of bias	-
Ruzyllo (CL3-023) 15mg, 2007	ivabradine 15mg	amlodipine			Low risk of bias	-
Ruzyllo (CL3-023) 20mg, 2007	ivabradine 20mg	amlodipine			Low risk of bias	-
INITIATIVE (CL3-017, Tardif) 15mg, 2005	ivabradine 15mg	atenolol			Low risk of bias	-
INITIATIVE (CL3-017, Tardif) 20mg, 2005	ivabradine 20mg	atenolol			Low risk of bias	-
myocardial revascularization
not classified
Serruys Benestent 2, 1998	stent	balloon angioplasty				suggesting
Versaci , 1997	stent	balloon angioplasty				suggesting
Fischman STRESS, 1994	stent	balloon angioplasty				suggesting
Serruys Benestent, 1994	stent	balloon angioplasty				suggesting
Moer, 2001	stent	balloon angioplasty				negative
Doucet, 2001	stent	balloon angioplasty				negative
Koning, 2001	stent	balloon angioplasty				suggesting
Park, 2000	stent	balloon angioplasty				negative
Lotan, 2000	stent	balloon angioplasty				suggesting
Weaver, 2000	stent	balloon angioplasty				suggesting
Dangas, 2000	stent	balloon angioplasty				negative
Fluck, 2000	stent	balloon angioplasty				negative
Lafont, 2000	stent	balloon angioplasty				negative
Witkowski, 2000	stent	balloon angioplasty				negative
Kastrati, 2000	stent	balloon angioplasty				negative
Di Marlo, 2000	stent	balloon angioplasty				negative
Serruys, 2000	stent	balloon angioplasty				negative
Lincoff (EPISTENT), 1999        NCT	stent	balloon angioplasty				suggesting
Buller, 1999	stent	balloon angioplasty				suggesting
Betriu, 1999	stent	balloon angioplasty				suggesting
Hoher, 1999	stent	balloon angioplasty				suggesting
Sievert, 1999	stent	balloon angioplasty				suggesting
Eeckout, 1996	stent	balloon angioplasty				negative
Sirnes, 1996	stent	balloon angioplasty				suggesting
Savage, 1998	stent	balloon angioplasty				negative
Erbel, 1998	stent	balloon angioplasty				suggesting
Rubartelli, 1998	stent	balloon angioplasty				suggesting
Hancock, 1998	stent	balloon angioplasty				suggesting
Rodriguez, 1998	stent	balloon angioplasty				negative
EVOLVE, 2012      NCT	bioabsorbable polymer EES	everolimus eluting stent				-
FAME II, 2012        NCT	FFR-guided PCI	no PCI				suggesting
Leon (high dose), 2005	TMR	placebo			Low risk of bias	negative
SYNTAX (diabetic), 2010      NCT	PCI with drug-eluting stents	CABG			Exploratory	-
ARTS, 2001	stent	CABG				negative
ERACI II, 2003	stent	CABG			Risk of bias	suggesting
SOS, 2002            NCT	stent	CABG			Risk of bias	suggesting
CARDia (PCI), 2008	stent	CABG			Risk of bias	negative
LEMANS, 2002      NCT	stent	CABG			Exploratory	negative
MASS II, 2007	stent	CABG			Risk of bias	negative
Myoprotect, 2004	stent	CABG			Exploratory	-
Cisowski	stent	E-ACAB				negative
STICH (vs med), 2011    NCT	CABG	medical treatment			Risk of bias	suggesting
CASS subgroup, 1985	CABG	medical treatment			Exploratory	suggesting
Schofield, 1999	TMR	medical treatment			Risk of bias	negative
Allen, 1999	TMR	medical treatment			Risk of bias	negative
Frazier, 1999	TMR	medical treatment			Risk of bias	negative
ATLANTIC (Burkhoff), 1999	TMR	medical treatment			Risk of bias	negative
Aaberge, 2000	TMR	medical treatment			Risk of bias	negative
Huikeshoven, 2003	TMR	medical treatment			Exploratory	-
PACIFIC, 2000	TMR	medical treatment			Risk of bias	negative
Stone, 2002	TMR	medical treatment			Risk of bias	negative
Salem, 2004	TMR	medical treatment			Low risk of bias	negative
van der Sloot, 2004	TMR	medical treatment			Exploratory	negative
March, 1999	TMR	medical treatment			Exploratory	-
Gray, 2003	TMR	medical treatment			Exploratory	negative
Diegeler, 2002	stent	MIDCAB			Risk of bias	negative
Drenth, 2002	stent	MIDCAB			Risk of bias	negative
Grip, 2001	stent	MIDCAB				negative
SIMA, 2000	stent	MIDCAB				negative
Kim, 2005	stent	MIDCAB			Risk of bias	-
OCTOSTENT, 2003        NCT	stent	OPCAB			Risk of bias	negative
Costar II, 2008      NCT	CoStar stent	paclitaxel eluting stent			Risk of bias	negative
ISAR-TEST-4 (biodegradable polymer), 2009    NCT	sirolimus biodegradable polymer	sirolimus eluting stent			Risk of bias	negative
Galiñanes, 2004	TMR	thoracic sympathectomy			Exploratory	negative
angioplasty
AMIST (Reeves), 2004	angioplasty	MIDCAB			Risk of bias	-
biolimus eluting stent
LEADERS, 2008      NCT	biolimus eluting stent	sirolimus eluting stent				negative
Coronary Artery Bypass Surgery
Allen, 2000	TMR+CABG	CABG				-
STICH (ventricular reconstruction), 2009      NCT	CABG+surgical ventricular reconstruction	CABG				negative
Loubani, 2003	TMR+CABG	CABG			Exploratory	-
Zhao, 2006	TMR+CABG	CABG			Exploratory	-
MASS II, 2007	CABG	medical treatment				negative
VA, 1984	CABG	medical treatment				suggesting
ECSS (European), 1988	CABG	medical treatment				suggesting
CASS, 1983    NCT	CABG	medical treatment				negative
Texas, 1977	CABG	medical treatment				negative
Oregon, 1979	CABG	medical treatment				negative
New zealand 1, 1981	CABG	medical treatment				negative
BARI 2D, 2009          NCT	CABG or PCI	medical treatment			Risk of bias	negative
dactinomycin eluting stent
ACTION, 2004	dactinomycin eluting stent	bare-metal stent				suggesting
drug-eluting stents
Boudriot, 2008	DES	CABG			Exploratory	negative
FREEDOM, 2012      NCT	PCI with drug-eluting stents	CABG			Risk of bias	negative
Hong, 2005	PCI withdrug-eluting stents	CABG			Risk of bias	-
everolimus eluting stent
FUTURE I, 2004	everolimus eluting stent	bare-metal stent				negative
FUTURE II, 2006	everolimus eluting stent	bare-metal stent			Low risk of bias	-
SPIRIT I, 2005    NCT	everolimus eluting stent	bare-metal stent			Exploratory	negative
SPIRIT II, 2006      NCT	everolimus eluting stent	paclitaxel eluting stent			Risk of bias	negative
SPIRIT IV, 2010          NCT	everolimus eluting stent	paclitaxel eluting stent			Risk of bias	suggesting